Droplet-based bioprinting (DBB) offers greater advantages due to its simplicity and agility with precise control on deposition of biologics including cells, growth factors, genes, drugs and biomaterials, and has been a prominent technology in the bioprinting community. Due to its immense versatility, DBB technology has been adopted by various application areas, including but not limited to, tissue engineering and regenerative medicine, transplantation and clinics, pharmaceutics and high-throughput screening, and cancer research. Despite the great benefits, the technology currently faces several challenges such as a narrow range of available bioink materials, bioprinting-induced cell damage at substantial levels, limited mechanical and structural integrity of bioprinted constructs, and restrictions on the size of constructs due to lack of vascularization and porosity. This paper presents a first-time review of DBB and comprehensively covers the existing DBB modalities including inkjet, electrohydrodynamic, acoustic, and micro-valve bioprinting. The recent notable studies are highlighted, the relevant bioink biomaterials and bioprinters are expounded, the application areas are presented, and the future prospects are provided to the reader.
Introduction
Three-dimensional (3D) bioprinting aims to fabricate tissue and organ constructs by selectively depositing biologics, such as living cells, biomaterials, drugs, growth factors and genes, in a layer-bylayer fashion [1e4] . It currently enables fabrication of scaffoldbased or scaffold-free tissue and organ constructs [5] , minitissues [3] and organ-on-a-chip models [6e9], and is envisioned to facilitate fabrication of functional replacement human organs such as heart, liver and kidney in the future [10] . However, bioprinting of such organs at present is impractical because of the challenges such as the need for built-in vascularization at the single-cell level and complex-heterocellular tissue patterning, and the development of biodegradable as well as biomimetic materials which are bioprintable while enabling rapid cell growth and proliferation [2, 3, 11] . Despite these challenges, 3D bioprinting serves in several other application areas. For example, 3D tissue models [1, 12] can improve in-vitro drug testing by replacing twodimensional (2D) cell culture and animal models as animal models are not effective at predicting human toxicological and pathophysiological responses [13] and 2D culture models do not closely mimic complex 3D micro-tissue environment [10, 12, 14] . Bioprinted tissues have also been used in tissue engineering and regenerative medicine such as bioprinted bone and cartilage which can help in musculoskeletal injury healing and rehabilitation [2, 3, 15] . Furthermore, in-situ bioprinting, technology enabling bioprinting directly into lesion sites in surgery settings, can regenerate complex large tissues through neo-vascularization driven by nature in human body [4, 16, 17] . Overall, 3D bioprinting provides an opportunity to envision radical solutions to existing medical and healthcare problems.
Bioprinting offers three main types of modalities including laser-[18e20], droplet-[21e24] and extrusion-based bioprinting [25] . Despite the commonly used extrusion-based bioprinting and the high-precision laser-based bioprinting, droplet-based bioprinting (DBB) offers several advantages due to its simplicity, agility, versatility and the great control over the deposition pattern. It enables bioprinting with controlled volumes of bioink deposition at predefined locations [3] facilitating spatially heterocellular constructs with well-defined positioning of cells [11] .
Droplet-based bioprinting has its roots in inkjet printing technology, which has its beginnings in the 1950s when Elmqvist of Siemens patented the first practical inkjet device in 1951 [26] . Later, Sweet from Stanford University spearheaded the development of continuous-inkjet (CIJ) printing system in 1960s. Later, Zoltan, Kyser, and Sears pioneered the development of drop-on-demand (DOD) inkjet printing system in 1970s. Their invention was licensed in the first commercial DOD inkjet printer, the Siemens PT-80, in 1977. The idea of printing biologics was first introduced by Klebe in 1987 when he used a commercially-available HewlettPackard (HP) thermal DOD inkjet printer to deposit a bioink solution comprising collagen and fibronectin [27] . Afterwards, the first inkjet-based 3D printer was developed by Objet Geometries in 2000 [28] . In 2003, Boland demonstrated the feasibility of using a modified thermal DOD inkjet printer to deposit living cells in a viable form [29] and introduced the concept of inkjet bioprinting [30] . Subsequently, Nakamura's group successfully fabricated viable 3D tubular tissue constructs using a commercially available electrostatic DOD inkjet printer [31] . Later, several research groups have successfully adopted DBB technologies for bioprinting of a wide array of cells for various purposes, including but not limited to, bioprinting for stem cell research [17,32e34] , tissue engineering [17, 24, 35, 36] , controlled release [37] , transplantation [24, 35] , drug screening [38] , high-throughput arrays [39] , and cancer research [36, 40] .
In this paper, we present a first-time and thorough review of DBB technology including the modalities used with a comprehensive discussion on their working mechanisms, a detailed comparison of DBB with other bioprinting modalities, recent achievements in DBB, and bioink materials and bioprinters used in DBB. The application areas are discussed and future prospects with highly exciting directions are provided to the reader.
Droplet-based bioprinting

Modalities of droplet-based bioprinting
Droplet-based bioprinting, as shown in Fig. 1 , comprises inkjet [3,11,21,22,27,41e43] , acoustic-droplet-ejection (or simply acoustic) [44] and micro-valve bioprinting [32, 33, 40, 45, 46] . Inkjet bioprinting is classified into three: (i) CIJ, (ii) DOD and (iii) EHD jetting. Continuous-inkjet bioprinting leverages Rayleigh-Plateau instability to break bioink jets into droplets. Drop-on-demand bioprinting, on the other hand, uses thermal or piezoelectric actuators, or electrostatic forces to generate droplets. In contrast, electrohydrodynamic jet (EHD) bioprinting uses high-ranges of electric voltage to eject droplets. Whereas, acoustic bioprinting uses acoustic waves to produce droplets and micro-valve bioprinting uses a solenoid pump to eject droplets.
Inkjet bioprinting
Inkjet bioprinting physically manipulates a bioink solution to generate droplets. It leverages gravity, atmospheric pressure and the fluid mechanics of the bioink solution to eject droplets onto a receiving substrate.
2.1.1.1. Continuous-inkjet bioprinting. In CIJ bioprinting, the bioink solution is forced under pressure through a nozzle, which subsequently breaks up into a stream of droplets owing to RayleighPlateau instability [47] as illustrated in Fig. 2A1 . The phenomenon of Rayleigh-Plateau instability has been described elsewhere in details [48] but briefly, a cylindrical volume of liquid jet is perturbed by several factors including but not limited to the potential energy owing to surface energy of the jet and the kinetic energy due to motion of the jet. When the wavelength of the perturbed jet exceeds its initial radius by a certain limit (such that the product of the wave number (k) (the number of waves per unit length) and the initial jet radius (R 0 ) is less than 1 (kR 0 < 1)), the perturbation grows exponentially and eventually the jet distorts itself to minimize its potential energy and breaks up into a stream of droplets.
Drop-on-demand inkjet bioprinting.
Drop-on-demand inkjet bioprinting is preferred over CIJ bioprinting for tissue bioprinting purposes. Drop-on-demand inkjet bioprinters generate droplets when required, which makes them more economical, handy to control and easy to pattern biologics [49] . Drop-ondemand bioprinters consist of a single or multiple printheads. Each printhead contains a fluid chamber and a single or multiple nozzles. The bioink stored in the fluid chamber is held in place by the surface tension at the nozzle orifice [49] . Pressure pulses are introduced in the fluid chamber through means of a thermal or a piezoelectric or an electrostatic actuator such that a droplet is ejected when the bioink overcomes the surface tension. Some printhead assemblies may require back pressure (pneumatic pressure (static pressure through means of pressurized-air) and/or vacuum) to supplement the pressure pulses for droplet generation. Drop-on-demand inkjet bioprinters rely on three different mechanisms to generate droplets including (i) thermal inkjet (TIJ), (ii) Fig. 1 . Classification of droplet-based bioprinting into inkjet, acoustic, and micro-valve bioprinting modalities. Inkjet bioprinting is further classified into continuous inkjet, drop-ondemand and electrohydrodynamic jetting modalities. Drop-on-demand inkjet bioprinting comprises thermal, piezoelectric and electrostatic techniques. piezoelectric inkjet (PIJ) and (iii) electrostatic bioprinting. Thermal inkjet bioprinters generate droplets using a thermal actuator whereas PIJ bioprinters generate droplets using a piezoelectric actuator [50] . The two techniques are identical in other aspects. Electrostatic bioprinting, in contrast, ejects droplets using an electrostatic force [31, 51] .
2.1.1.2.1. Thermal inkjet bioprinting. The thermal actuator in TIJ bioprinting locally heats the bioink solution when a voltage pulse is applied. The localized heating forms a vapor bubble as shown in Fig. 2A2 . Subsequently, the bubble expands rapidly and collapses (explodes), which generates a pressure pulse inside the fluid chamber [52, 53] . Consequently, the bioink overcomes the surface tension at the nozzle orifice and a droplet is ejected. Thermal inkjet bioprinters are capable of dispensing various biologics such as proteins and mammalian cells and are summarized in Table 1 .
The bioprinted cells retained their functional phenotype and genotype, and proliferation capacity [17,54e56] . In summary, bioprinting studies pertaining TIJ bioprinting technology to date have been to assess its impact on the functionality of bioprinted cells. For example, Fig. 3A1e2 show TIJ-bioprinted neurons tagged with neural markers at 15 days after bioprinting. As seen in the figure, TIJ bioprinting did not affect the neuronal phenotype and electrophysiological functions of the bioprinted neurons. Furthermore, a myriad of studies have utilized modified commercial 2D thermal inkjet printers and explored their role in tissue regeneration such as cardiac tissue (see Fig. 3B ) [57] , vascular tissue [52] and in-situ cartilage repair [56] .
2.1.1.2.2. Piezoelectric inkjet bioprinting. Piezoelectric bioprinters, similar to TIJ bioprinters, are suitable for bioprinting various biologics. The piezoelectric actuator in PIJ bioprinting changes its shape when a voltage pulse is applied, as depicted in Fig. 2A3 . This deforms the fluid chamber [50] , in which a sudden change in the volume of the fluid chamber causes a pressure wave. As a result, the surface tension at the nozzle orifice is overcome and a droplet of the bioink is ejected [58] . Overall, studies on PIJ bioprinting technology have thus far investigated the feasibility and possibility of fabricating 3D tissue constructs [9, 11, 59, 60] . For example, Fig. 3C depicts a PIJ-bioprinted vascular-like tissue construct with horizontal and vertical bifurcations. The tissue construct comprising alginate and NIH3T3 cells was fabricated by a single nozzle PIJ bioprinter. Further, some studies optimized process parameters, including the bioink constituents [61] , piezoelectric element actuation modes (pull-push and push-pull) [62] , and voltage pulse characteristics (amplitude, rise and fall times, dwell time, echo time, and frequency) [11, 60] , to improve process efficiency. Furthermore, few other studies attempted to improve process reliability [63] and control the number of encapsulated cells in ejected droplets for potential applications in the areas of diagnostics, therapeutics and cell biology [62, 64] .
2.1.1.2.3. Electrostatic bioprinting. Electrostatic bioprinters, identical to PIJ bioprinters, generate droplets by temporarily increasing the volume of the fluid chamber, without heating the bioink unlike TIJ bioprinters [51] . The brief increase in the volume of the fluid chamber as well as the bioink solution is achieved through the means of a pressure plate as shown in Fig. 2A4 . The pressure plate deflects when a voltage pulse is applied between the plate itself and an electrode. The pressure plate regains its original shape in the absence of the voltage pulse and subsequently ejects droplets. Electrostatic bioprinters have been primarily used by Nakamura's group [31] to fabricate 3D acellular (see Fig. 3D ) as well as cellular constructs comprising of HeLa cells.
2.1.1.3. Electrohydrodynamic jet bioprinting. Drop-on-demand bioprinters generate droplets by propelling bioink solutions through a nozzle. Hence, a very high level of pressure is required when ejecting cell-laden droplets through a nozzle with an extremely small orifice diameter, which is at times harmful to cells. In contrast, EHD bioprinters use an electric field to pull the bioink droplets through the orifice obviating the need for a substantially high pressure [42] . As a result, EHD bioprinters are ideal for bioprinting applications requiring nozzles with very small orifice diameters ( 100 mm) and highly concentrated bioinks (up to 20% weight by volume) [41] . The working mechanism of EHD bioprinting is illustrated in Fig. 2A5 [42, 65, 66] , where a bioink solution is fed through a metallic nozzle using a certain back pressure such that the bioink forms a spherical meniscus at the tip of the nozzle owing to the surface tension [67] . A high voltage range (0.5 kVe20 kV) [66, 68] is applied between the nozzle and the substrate, which generates an electric field (as a function of the applied voltage and the distance between the nozzle and the substrate) between them. As a result, the electric field leads to the accumulation of mobile ions in the bioink near the surface of the suspended bioink meniscus. Subsequently, the Columbic or the electrostatic repulsions between the ions deform the meniscus into a conical shape called a "Taylor cone." Consequently, bioink droplets are ejected when the electrostatic stresses overcome the surface tension at the orifice under a sufficiently high voltage depending on the process parameters. The strength of the electric field (applied voltage), the bioink flow rate and the bioink properties (including cell type and concentration [69] ) determine the jetting mode [42, 70] and cell viability [71] . Dripping mode is observed at low voltages and flow rates, whereas streams of distinct droplets are seen at intermediate voltages and/or flow rates. At the same time, a continuous stream of the bioink, known as cone-jet-mode (continuous presence of a Taylor cone), is observed at high voltages.
Although process parameters do not significantly affect the cell viability (see Table 2 ) and genomic expression immediately after bioprinting, applied voltage, cell concentration and bioink constituents can collectively affect the long-term post-bioprinting cell viability [71] . The applied voltage determines the ejected droplets size [43, 71] whereas bioink constituents (such as hydrogels including but not limited to crosslinked alginate, collagen and fibrin) and concentration used for cell encapsulation alter the diffusion of media. Hence, the droplet size and bioink constituents affect media transport to the encapsulated cells. The cell concentration also affects the number of cells encapsulated in each droplet and thus the availability of media to individual cells. In general, the droplets size decreases when the applied voltage increases and the media transport is not effective when the droplet size exceeds 400 mm.
Electrohydrodynamic jet bioprinting studies to date have investigated the practicality of bioprinting living cells and for understanding the effect of process parameters on characteristics of ejected droplets. For example, Fig. 3E shows EHD-bioprinted porcine vascular smooth muscle cells (PVSMCs) after 40 days Fig. 2 . Mechanisms of droplet-based bioprinting. (A) Inkjet bioprinting techniques: (A1) continuous-ink-jetting relies on Rayleigh-Plateau instability, which breaks bioink jets into droplets; (A2) thermal drop-on-demand bioprinting employs a thermal actuator to locally heat bioink solutions to generate droplets; (A3) piezoelectric drop-on-demand bioprinting depends on radial deformation of a piezoelectric actuator to generate droplets; (A4) electrostatic bioprinting relies on deflection of pressure plate to generate droplets; (A5) electrohydrodynamic jetting uses an electric field, resulting from the electric potential difference between the printhead and the substrate, to pull a stream of bioink droplets through the printhead orifice. (B) Acoustic-droplet ejection relies on a gentle acoustic field generated by an acoustic actuator to eject droplets from an open pool of bioink solution.
(C) Micro-valve (solenoid) bioprinting operates with an electromechanical valve to dispense droplets. University of London EHD as a viable bioprinting strategy using Jurkat cells [41] , CAD (Cath.-a-differentiated) mouse neural cells [22] , human astrocytoma cells [69] , white blood cells, erythrocytes [155] , and THPpost-bioprinting. Subsequent, flow cytometric analysis indicated that the bioprinted cells retained their viability [72] . In summary, EHD bioprinters generate a continuous jet or a stream of droplets at a time rather than a single droplet. Hence, they are not suitable for bioprinting applications requiring very accurate placement of cells.
Acoustic bioprinting
Acoustic bioprinting, as illustrated in Fig. 2C , employs a gentle acoustic field to eject droplets from an open pool unlike inkjet bioprinting, which ejects droplets through a nozzle [23] . As a result, the bioink and the constituent living cells are not exposed to detrimental stressors such as heat, high pressure, large voltage, and significant shear stress during droplet ejection. Typically, an acoustic bioprinter consists of a single or an array of 2D microfluidic channels, in which the bioink is held in place owing to the surface tension at the small channel exit. Further, the bioprinter setup generally consists of a piezoelectric substrate and interdigitated gold rings placed on the substrate to generate surface acoustic waves on demand. The waves are circular in geometry and form an acoustic focal point at the interface between the air and the bioink near the channel exit. The droplets are ejected when the force, exerted by the acoustic radiation at the focal point, exceeds the surface tension at the exit of the channel [23, 73] .
Bioprinting often involves printhead and/or substrate movement; however, a moving printhead and/or a substrate can introduce undesirable disturbances in acoustic-based bioprinting when compared to nozzle based systems including inkjet bioprinters. Consequently, the disturbances can bring loss of control over the droplet ejection. In addition, gentle acoustic fields may not be capable of ejecting droplets of viscous bioinks such as hydrogels with high cell concentrations. Sadly, studies investigating acousticbased bioprinting are very few to date. Acoustic-based bioprinting has enabled bioprinting of a myriad of cell types. For example, Fig. 3F shows acoustically bioprinted AML-12 cells after 12 days post bioprinting [23] . The bioprinted cells were viable and became confluent in 12 days.
Micro-valve bioprinting
Micro-valve bioprinting uses an electromechanical valve to generate droplets as shown in Fig. 2D [45, 46, 74] . The bioink in the fluid chamber is pressurized (back pressure) and the nozzle orifice is gated by a micro-valve. A typical micro-valve consists of a solenoid coil and a plunger which blocks the orifice. The valve coil generates a magnetic field when a voltage pulse is applied and the magnetic field pulls the plunger upwards. As a result, the nozzle is unblocked and the bioink is ejected out when the back pressure is sufficiently large enough to overcome the surface tension at the orifice. The back pressure and the valve-gating time determine the mode of the droplet generation, either CIJ or DOD.
Micro-valve bioprinters are favorable for bioprinting various proteins and cells. Process parameters, such as pneumatic pressure, nozzle geometry, cell concentration and the bioink constituents, determine the droplet volume as well as the cell viability [32] . 10 6 cells/ml density in culture media or keratinocytes with 10 6 cells/ml density in culture media) of 250 mm in diameter (8.1 ± 2.1 nL) [46] . At the same time, the same nozzle with a pneumatic pressure of 13.79 kPa (2 psi) and a valve open/close duration of 600 ms generated collagen droplets (2.05 mg/ml of rat tail origin Type I collagen precursor) of 240 mm in diameter (7.6 ± 2.7 nL). The bioprinted cells retained their functionality, phenotype and genotype, and proliferation capacity (see Fig. 3G1e3 ) [46] . In addition, the differentiation capacity of human stem cells were not affected by the bioprinting process [32, 33] . In summary, studies pertaining micro-valve bioprinting technology to date have examined the impact of bioprinting process on cell viability and functionality. Indeed, studies demonstrating the fabrication of complex 3D tissue constructs, similar to PIJ studies [11, 60] , are lacking. Overall, micro-valve bioprinters require lowrange of pneumatic pressure compare to that of PIJ bioprinters and hence they are less prone cell injury and damage [46] . However, micro-valve bioprinters dispense larger droplets than other DBB modalities (including TIJ, PIJ and EHD bioprinters) when identical nozzles are used [44] . Thus, the resolution of micro-valve bioprinters is lower than that of TIJ and PIJ bioprinters.
Droplet-substrate interactions
In addition to jet formation, impingement of a droplet onto the substrate is also crucial during DBB as it affects the fidelity and spreading of the droplet. While the ultimate goal of bioprinting is to pattern the cells and fabricate 3D tissue constructs, the ideal placement of droplets should accommodate the preservation of the droplet integrity as splashing or spreading of the droplet results in displacement of the deposited cells from their desired position or structural failure in 3D bioprinting. For viscoelastic hydrogels used in DBB, there exist two major impingement characteristics including splashing and spreading of the droplet. In splashing, the droplet disintegrates into secondary droplets after colliding with a substrate. In spreading, on the other hand, the droplet spreads over the surface and expands its surface area. According to Worthington, the droplet shape highly depends on the velocity of the droplet, where higher velocity generates splashing and lower velocity leads to spreading [75] . According to Weber, the critical number (W e ) of droplet splashing is formulated as:
where r is the density of the liquid, d is the characteristics length which corresponds to the diameter of the droplet, U is the velocity and s is the surface tension. In general, larger Weber numbers generates splashes and lower ones leads to spreading. As these properties are important for the droplet formation [76e78], properties of the substrate is also important as the factors including but not limited to wettability of the surface, surface roughness as well as viscous forces [79] . Furthermore, the spreading of the droplet occurs faster than its polymerization in a typical bioprinting setup [61] and the parameters associated with the crosslinking mechanism (i.e., ionic crosslinker solution concentration) influences the spreading behavior of the droplet [55] . Droplet-substrate interactions broadly consist of two regimes from a fluid mechanics perspective [77, 80] . The first is the dynamic regime during which the kinetic energy of the droplet is dissipated. The second is the viscous dissipation regime during which surface energy interactions between the droplet and the substrate determine the spreading of the droplet to an equilibrium shape. In addition, gravity has minimal influence on landing and spreading of the droplet [81] .
Transitioning from 2D (on a substrate) to 3D bioprinting necessitates a 3D printing mechanism, which enables fabrication of 3D constructs through deposition of droplets in a layer-by-layer fashion. Depending on the utilized hydrogel and its crosslinking mechanisms, four types of 3D printing schemes have been utilized in fabrication of tissue constructs including (i) alternating printing of the bioink and the crosslinker solutions (Fig. 4A ), (ii) bioprinting of the bioink solution into a reservoir filled with the crosslinker solution ( Fig. 4B ), (iii) bioprinting of the bioink solution followed by spraying the crosslinker solution on top (Fig. 4C) , and (iv) bioprinting of the bioink solution followed by exposing it to an ultraviolet (UV) source (Fig. 4D) . As fabricating scale-up tissue constructs necessitates the integration of vascular networks, such vascularization can be generated by printing thermallycrosslinking sacrificial materials (i.e., gelatin) and liquefying them thereafter, which is also discussed in Section 5.2.1 under vascular tissue fabrication.
The resolution at which the 3D construct is fabricated depends on various factors including the volume and velocity of ejected droplets, droplet-substrate and droplet-droplet interactions, and the applied crosslinking mechanism. The volume of ejected droplets is mediated by several operating parameters such as the bioink material characteristics, the printhead geometry (orifice diameter) and its actuation voltage pulse characteristics [23, 32, 36, 43, 46, 71, 82, 83] . For example, the width of each coalesced line in Fig. 4A depends on several fabrication parameters including the volume of droplets, the spacing between droplets and the printing speed, which consequently controls the bioprinting resolution [11, 31, 84] . In addition, how droplets interact with the substrate affects the spreading behavior of the droplet, which consequently affects the bioprinting resolution [76, 77, 81, 85] .
Droplet-based bioprinters
Droplet-based bioprinting was pioneered by Klebe in the 1980s and later by Boland's group at Clemson University in early 2000s. Commercially available Canon and HP paper printers, based on TIJ mechanism, were adapted to bioprint various tissue constructs comprising proteins and cells. However, paper printers are not suitable for bioprinting as ink cartridges are prone to clogging and are difficult to clean when bioprinting viscous bioinks such as living cells with collagen. Additionally, printheads move along only one axis and are not capable of bioprinting even in 2D without introducing the motion capability to the substrate. Nakamura's group at University of Toyama circumvented the movement limitations of the paper printers by building a custom bioprinter in mid-2000s. The bioprinter was built using commercially available stepper motors and EPSON SEA-Jet™ (electrostatic) printheads. The bioprinter was used to fabricate 3D hollow tubular tissue constructs comprising HeLa cells [31] to further Boland's work [30] .
Commercially available DOD printheads, such as EPSON SEAJet™, Fuji piezoelectric Dimatix™, and Xaar-126 piezoelectric printheads consist of several nozzles connected to a single fluid chamber. The ejected droplets range from 1 to 100 pl (with droplet diameters of 10e60 mm), which are highly small and thus limit the use of some large cell types and bioink constituents. At the same time, single nozzle piezoelectric printheads, such as MicroFab printheads, offer a greater control over the droplet generation (number of droplets) and the droplet placement, and are more suitable for fabricating complex 3D tissue constructs. However, small secondary droplets, known as satellite droplets [86] , often accompany the primary droplets affecting the bioprinting resolution [60] . In addition, printheads are prone to clogging if the bioink viscosity is high.
Micro-valve bioprinters, in contrast, are suitable for bioprinting viscous bioinks as the droplets ejection is primarily governed by the valve opening time. However, they are not suitable for highresolution bioprinting applications as the diameter of the ejected droplets [87] is greater when compared to other DBB modalities under the identical nozzle orifice diameter [44] . According to [44] , the smallest droplets that can be generated by micro-valve bioprinters are 100 mm in diameter as opposed to 50 mm of inkjet (thermal and piezoelectric) bioprinters and 10 mm of acoustic bioprinters. Biofactory is a popular commercial micro-valve bioprinter and the smallest printable droplet size using the Biofactory bioprinter ranges from 5 to 10 nL (>100 mm) [126] . Although, EHD bioprinters generate droplets that are substantially smaller than 10% PEG and 5% GelMa [98] 4 [98] Thrombin [52] 200 unit/ml [52] N/A Piezoelectric DOD 21.5e120 mm [11, 60, 63, 150] 50e100 mm [11, 63, 82, 150] 70e95% [9, 11, 29, 60] Alginate (NaAlg from SigmaAldrich) [11, 158] 2% [11, 158] the nozzle orifice opening, the bioprinters are not capable of ejecting a single droplet at a time as they eject a stream of multiple droplets or a jet. Hence, EHD bioprinters are not suitable for high precision (precise placement of droplets) bioprinting applications.
Overall, controlling the number of cells to be encapsulated in a single droplet is still a challenge, regardless of the DBB modality. Hence, an ideal DBB bioprinter that offers precise control over the number of encapsulated cells is highly desired. Also, the bioprinter has to deposit multiple cell types as well as various viscous bioinks simultaneously without experiencing any clogging issues. Furthermore, the bioprinter has to precisely place droplets without any accompanying satellite droplets or jets. Unfortunately, such a bioprinter is currently far from the reality and certain features are always compromised while choosing bioprinters for a specific application. A comparative evaluation of the presented DBB modalities is presented in details in Table 2 .
Biomaterials used in droplet-based bioprinting
A bioprintable material comprising various biologics (i.e., cells, growth factors, deoxyribonucleic acid (DNA) or drugs loaded in a delivery medium such as media or hydrogels) which is employed to fabricate 3D constructs with or without the use of external stimulations is rightfully referred to as 'bioink.' Essential characteristics of bioink include low viscosity, suitable biodegradability and biocompatibility, enhanced cell adhesive properties, bioprintability and high mechanical strength. However, such characteristics limit the range of exploitable biomaterials for DBB. Therefore, a limited range of hydrogels are available as bioink in DBB. Alternatively, hydrogels are also used as a substrate material when their viscosity is higher and/or the nozzle orifice diameter is extremely small. Hence, cells and other biologics are directly bioprinted into them.
The bioink consideration
A limited range of hydrogels including alginate, collagen, fibrin, methacrylated gelatin (GelMA) and polyethylene glycol (PEG), have been used in DBB due to their own or their crosslinkers' ease of ejectability and the compatibility of their crosslinking mechanism with different DBB modalities.
Alginate, a naturally derived polysaccharide molecule, is a frequently used hydrogel in DBB [32] . ), it yields a crosslinked hydrogel network. Exploiting this crosslinking mechanism of alginate with CaCl 2 , Atala's group fabricated heterogeneous tissue constructs comprising human amniotic fluidderived stem cells (hAFSCs), canine smooth muscle cells (dSMCs), and bovine aortic endothelial cells (bECs) [17] . Alginate was also combined with several other materials to enhance the mechanical and functional properties of the fabricated constructs. Blaeser's group, for instance, fabricated a bifurcated vascular tissue construct using a composite blend of 3% (w/v) low melting agarose and 3% (w/v) low viscosity alginate [89] . The bioprinting process was performed under nontoxic fluorocarbon, which provided the necessary buoyancy forces needed to support the soft tissue structure. Additionally, Boland and his coworkers bioprinted the crosslinking solution (CaCl 2 ) using a modified HP DeskJet inkjet printer to fabricate a heart-like tissue construct with connected ventricles [57] . In another study, Huang's group mixed 3T3 fibroblast cells in 1% sodium alginate solution and bioprinted it into the crosslinker pool to fabricate zigzag cell-laden tubular constructs [11] . Similarly, alginate comprising hepatocyte-like cells, which were obtained through directed differentiation of human inducedpluripotent stem cells (hiPSCs), was bioprinted to fabricate a 3D mini-liver tissue model [32] .
Collagen type-I is a triple helical protein which is a major component of ECM of several tissues in the human body [90] . It is a thermosensitive hydrogel and has been extensively exploited in tissue engineering for fabrication of tissue constructs due to its biocompatibility and cell adhesive properties [91] . In one study Boland's group used it as a bioink constituent to investigate adhesion and proliferation of cells on collagen-coated cell repellant substrates [91] . Also, Boland's group fabricated a bilayer skin graft, which generated neoskin identical to native skin with microvessels [92] . In another study, fibrin-collagen bioink comprising one of the two cell types, AFSCs or mesenchymal stem cells (MSCs), was bioprinted into wound sites for treating surgical skin wounds [93] .
Methacrylated gelatin, a denatured collagen protein consisting of methacrylate groups conjugated to its amine side groups, has been increasingly used for engineering various tissues due to its appealing biological and controllable mechanical characteristics [94, 95] . Although polymers derived from natural sources closely mimic the native extracellular matrix (ECM), they are inferior in mechanical strength. Methacrylated gelatin, in contrast, forms a biomimetic [94] as well as an enzymatically degradable [96] hydrogel that is mechanically strong when photocrosslinked with UV light in presence of a photoinitiator. For example, Demirci's group incorporated GelMA and growth factors (bone morphogenetic protein 2 (BMP-2) and transforming growth factor beta 1 (TGF-b1)) as bioink constituents to imitate native fibrocartilage microenvironments which differentiated bioprinted hMSCs towards osteogenic and chondrogenic lineages spatially [33] .
Fibrin, a hydrogel formed by the reaction of thrombin with fibrinogen, supports extensive cell growth and proliferation [52] . It plays a significant role in wound healing and has been used to fabricate skin grafts [92, 93] . Boland's group used fibrin to engineer micro-capillaries by bioprinting human dermal microvascular endothelial cells (HMVECs)-laden thrombin and Ca 2þ solution on a fibrinogen substrate [52] . Employing TIJ bioprinting, HMVECs were precisely bioprinted on crosslinked fibrin. Bioprinted HMVECs aligned well in fibrin and formed into an extensive capillary network after 21 days of culture. In another study, the same group bioprinted alternating layers of neural cells and fibrin gel to fabricate viable neural constructs for potential neural engineering applications [54] . In another study, Atala's group used fibrin to engineer cartilage tissue with enhanced mechanical and functional properties employing a hybrid method involving electrospinning and micro-valve bioprinting [35] . Polyethylene glycol, a polyether-based material, yields photolabile polymers when functionalized (addition of functional groups) with diacrylate (DA) or methacrylate (MA) [97] . Due to its greater mechanical strength compared to naturally-derived polymers, such as alginate, fibrin, agarose and collagen type-I, PEG is extensively used in DBB. Further, PEG is water soluble and its mechanical properties are controllable through variation of its chemistry [98] . Altering the composition of PEG-based hydrogels and photocrosslinking them in presence of a photoinitiator enables the control of structural, functional and mechanical properties of fabricated tissues. PEG-based hydrogels employed for cartilage tissue engineering have not only induced ECM production but also supported growth and proliferation of chondrocytes [99] . In that particular study, Cui et al. functionalized PEG with methacryloyl chloride and cultured human articular chondrocytes on PEGDMA hydrogel [99] . Using TIJ bioprinting, 3D constructs were fabricated by photocrosslinking cell-laden PEGDMA hydrogel in a layer-bylayer fashion in the presence of I2959 photoinitiator. These cellladen hydrogel constructs were then stimulated with insulintransferrin-selenium (ITS) based medium supplemented with TGF-b1 and fibroblast growth factor (FGF-2). The study revealed high cell proliferation and chondrogenic ECM deposition on the printed constructs due to the synergistic action of these growth factors, which eventually led to neo-cartilage formation [56, 99] . In a similar study, acrylated-PEG was bioprinted with acrylatedpeptide containing the Arg-Gly-Asp (RGD) sequence (essential for cell adhesion), followed by photopolymerization of the each bioprinted layer, resulting in 3D constructs comprising hMSCs [98] . The bioprinted hMSCs were successfully differentiated towards osteogenic and chondrogenic lineages. In another study, bone marrow-derived hMSCs were suspended in PEGDMA in conjunction with bioactive glass (BG) and hydroxyapatite (HA) nanoparticles, and bioprinted using a TIJ bioprinter [100] . This approach allowed control over the spatial delivery of hMSCs and bioactive ceramic materials in the fabricated bone tissue constructs (with a diameter of 4 mm and a thickness of 4 mm).
There are a limited number of hydrogels that can be employed in DBB owing to very fine nozzle diameters. Therefore, it is essential to use bioinks with low viscosity to obviate nozzle clogging issues. Bioprintability, cost, crosslinking mechanisms, and viscosity are some of the factors which are essential to consider while selecting a bioink for DBB. Generally, natural hydrogels are preferred over synthetic ones as they possess inherent cell adhesive motifs and are able to mimic the ECM of the native tissue better. However natural hydrogels are mechanically poor and have higher or uncontrolled degradation rates. Natural hydrogels such as collagen is an integral protein found in extracellular matrices of most tissue types. Its ease of crosslinking under physiological temperature or increased pH makes it a suitable material for skin, cartilage, neural and vascular tissue engineering applications. Similarly, other naturally-derived hydrogels, such as fibrin and alginate, can be used for tissues that do not involve load bearing applications. Although synthetic hydrogels such as PEG do not inherently possess bioactive sites, they can be designed to conjugate the RGD sequence to enhance its cell adhesive properties. Additionally, synthetic hydrogels are mechanically strong and can be employed for bone tissue engineering applications. A comparison of the abovementioned hydrogels is presented in Table 3 .
The substrate consideration
In addition to bioprinting hydrogels, a myriad of endeavors has been made to bioprint macromolecules (i.e., growth factors, proteins or even cells in media) directly onto hydrogel substrates. By controlling the spatial distribution of growth factors on hydrogel substrate, differentiation of stem cell into specific lineages have been widely attempted. Phillippi et al. used cyanin-3-labeled BMP-2 in media as a bioink solution and bioprinted it on fibrin-coated glass slides using a PIJ bioprinter [101] . They spatially immobilized BMP-2 with a varying concentration according to a predesigned pattern and cultured primary muscle-derived stem cells (MDSCs) on the BMP-2 patterned surface. This led to the differentiation of MDSCs into multiple lineages, namely osteogenic and myogenic in that study. Another study conducted by Ilkhanizadeh et al. showed that the fate and differentiation ability of neural stem cells could be effectively controlled by inkjet bioprinting of various macromolecules, such as fibroblast growth factor-2 (FGF2), ciliary neurotrophic factor (CNTF) and fetal bovine serum (FBS), on neural stem cell-seeded polyacrylamide-based (PA) hydrogel substrates [102] .
Demirci's group fabricated coculture cancer models by bioprinting human ovarian cancer cells and fibroblasts in a controlled manner on Matrigel coated glass culture dish [40] . Collagen type I and fibrinogen has also been used as gel substrates for spatiallycontrolled bioprinting of HMVECs mixed in thrombin for fabricating skin grafts [92] . This bilayered skin graft comprising of keratinocytes and fibroblasts in collagen (as the top layer and bottom layer, respectively), and HMVECs encapsulated in fibrin network as the middle layer resulted in a portable construct, which was eventually placed on full thickness wounds in mice model for invivo studies. Polyacrylamide gel substrates have also been employed for micro-patterning proteins and cells by peeling off the protein from functionalized glass slides coated with PA substrates [103] . Poly(allylamine hydrochloride)/poly(styrene sulfonate) (PAH/PSS) based films were patterned on alginate gels for vascular tissue engineering by peeling off from the substrate as well [104] . These studies reveal the feasibility of bioprinting cells on gel substrates, and depending on the application, these substrate can be engineered to be peeled off for further studies.
A comparative evaluation: droplet-based bioprinting versus others
Droplet-based bioprinting has several advantages and disadvantages with respect to other bioprinting techniques, including extrusion-based bioprinting (mechanical [105e109], pneumatic [110e114] or valve-based [115e118]) or laser-based bioprinting (stereolithography [119] and its modifications [120] , laser-guidance direct writing [18, 121] and laser-induced forward transfer [19, 122, 123] ).
Droplet-based bioprinting technology is a multi-faceted technology. Highly complex heterocellular tissue constructs with different compositions of biologics (i.e., biomaterials, cells, growth factors, drugs, and genes) can be easily patterned when compared to extrusion-and laser-based bioprinting techniques as it is highly challenging to generate heterogeneity in a delicate manner using extrusion-based bioprinting and incorporating multiple types of biologics in laser-based bioprinting is difficult. While DBB has a process resolution higher than that of extrusion-based bioprinting and possesses a greater versatility in incorporating multiple biologics, DBB has attracted several researchers in the bioprinting community as well as researchers adopting bioprinting technology in other field of studies such as regenerative medicine and pharmaceutics [38, 124] . Moreover, it has a reasonable resolution comparable to laser-based bioprinting, which allows better control on the geometry and size of bioprinted constructs by mediating the gelation process precisely as crosslinker and precursor hydrogel solutions can be selectively deposited. This enables mighty control on swelling and shrinkage properties of the bioprinted constructs.
Droplet-based bioprinters are highly versatile and affordable, where a simple HP printer can be easily modified and used as a bioprinter [125] . A wide range of droplet-based bioprinters are commercially available within affordable price range [126] . If the reproducibility and flexibility becomes a concern, extra capabilities can be easily implemented with a reasonable additional cost. For example, printheads in DBB may not be suitable for certain bioink materials such as fibrous bioink (i.e., fibrinogen and collagen) and generate inconsistent results due to nozzle clogging or accumulation of cell debris or fibers anywhere in the line from reservoir to the nozzle in the tubing system. A commercial droplet-based bioprinter can be modified to overcome such issues by replacing the original dispenser with dispensers having larger nozzles or dispensers with different droplet generation mechanisms as the rest of bioprinter sub-components are common for all DBB modalities.
Droplet-based bioprinting technology is also user-friendly and easy to implement. It can be readily used by operators, who have limited exposure to the technology while generated computeraided design (CAD) models can be easily transferred to print out by simply pressing 'bioprint.' In other words, it has a non-steep learning curve circumventing the need for extensive experimentation, which is a major impediment in extrusion-based bioprinting as the operator needs to understand the shear-thinning behavior of hydrogels as well as their bioprintability on the printing stage.
The other advantage of DBB is that it facilitates rapid bioprinting through an array of nozzles in a highly reproducible manner. This capability enables rapid fabrication of an array of samples, which is highly desirable in high-throughput screening applications such as drug testing and cancer screening [36, 40, 64] . Producing highthroughput arrays using extrusion-based bioprinting, on the other hand, is highly challenging. In addition to its appealing features, DBB has a great translational potential in clinical use for [56, 98, 99] hMSCs (6 Â 10 6 cells/ml) [98, 100] conjugated PEG for DBB as well as bone and cartilage tissue engineering [98] ; Evaluation of bioactive ceramic nanoparticles in stimulating osteogenesis [100] tissue bioprinting. It is highly convenient for in-situ bioprinting purposes as defects (i.e., cranio-or maxilla-facial defects, skin burns or deep wounds) on human body can be easily reconstructed using DBB as DBB operates in a non-contact manner. The defects can be easily filled by jetting droplets from a distance. This feature also enables bioprinting of growth factors or other biologics onto existing tissue constructs as biologics can be selectively sprayed over them [37] . The non-contact nature of DBB processes alleviates other major issues observed in extrusion-based bioprinting such as collision between the printhead and the bioprinted constructs, or unexpected increase in clearance between the orifice and the receiving substrate. Despite these advantages, DBB possesses considerable limitations and drawbacks. One of the major limitations of DBB is the clogging of orifice during bioprinting process as highly small fragments in the bioink can accumulate within the orifice and obstruct the flow. This can sometimes necessitate the replacement of the entire orifice if the clogged material does not dissolve or cannot be removed. Because of the small orifice diameter ranging from 10 to 150 mm, as discussed before, a limited number of biomaterials are available for DBB such as low-viscosity hydrogels or their components. Thus, a wide majority of the bioink materials used in extrusion-based bioprinting, including cell aggregates, microcarriers and highly-viscous hydrogels [25] , cannot be used in DBB. Due to this issue, researchers have preferred to create substrates of hydrogels and bioprint cells or other biologics on them using cell media as a delivery medium [33] . This approach has been widely employed for bioprinting arrays of droplets for highthroughput screening [39] .
Although the non-contact nature of DBB provides great advantages as discussed before, gelation characteristics of printed droplets should be well experimented as ejected droplets can quickly gel in the air and do not assemble to the bioprinted substrate easily. The other limitation of DBB is the inability to fabricate mechanically strong and structurally well-integrated constructs due to the limited range of available bioink materials, particularly in high concentrations [127] . This can be however alleviated to some extent by infiltrating the bioprinted constructs within another biomaterial as a post-process. Alternatively, a reinforcement approach can also be employed, where nanofibers of stronger polymers can be reinforced into the inkjet bioprinted hydrogels using a hybrid fabrication setup [35] .
While DBB facilitates fabrication of constructs in a discontinuous manner, where discrete droplets are assembled in 3D, it is highly challenging to fabricate porous tissue constructs. Porous tissue constructs are favorable for perfusion purposes to facilitate sufficient media exchange and can be easily bioprinted using extrusion-or laser-(only stereolithography and its modifications) based bioprinting techniques. Using DBB, porous architecture can be created either using a plotting medium as a support material with the help of buoyancy or utilizing a two-step approach such as applying porogens or fugitive hydrogels. Lastly, as the resolution of DBB is higher than that of extrusion-based bioprinting, it takes a longer time to fabricate scalable tissue constructs, where some minor issues can be experienced such as change in the size of the construct due to swelling, contraction or dehydration (when not bioprinted into the medium).
Recent achievements and application areas
Droplet-based bioprinting has been widely used in the bioprinting community as well as other communities. In this section, recent achieves in the domain of DBB is presented and the applications areas are expounded.
Recent achievements in droplet-based bioprinting
Although clinical translation of DBB has been elusive, numerous recent breakthroughs in the areas of stem cell research, organs-onchip models and regenerative medicine including tissue regeneration using in-situ bioprinting may make it eventually inevitable. To begin with, DBB does not affect stem cells functionality and differentiation capacity [17, 32, 33, 98] . For example, Shu's group engineered 3D liver tissue models with hepatocytes derived from hiPSCs and human embryonic stem cells (hESCs) [32] . The group bioprinted a bioink solution (comprising hepatocytes and sodium alginate) using a micro-valve bioprinter to fabricate 3D tissue model (see Fig. 5A1eA2 ). During the bioprinting process, alternating layers of the bioink and crosslinker solutions (calcium chloride (CaCl 2 )) were bioprinted to enable the crosslinking of alginate. After 17 days post-bioprinting (after 23 days postdifferentiation), bioprinted cells maintained their differentiated phenotype, which was confirmed through the presence of hepatic markers such as hepatocyte nuclear factor 4 alpha (HNF4a) and albumin.
In another study, Atala's group demonstrated that bioprinted stem cells retained their functionality and the differentiation capacity both in vitro and in vivo [17] . The group bioprinted three different cell types, hAFSCs, dSMCs and bECs along with CaCl 2 solution using a TIJ bioprinter. Consecutive layers of cell-laden CaCl 2 crosslinker solution were bioprinted into a sodium alginatecollagen solution to fabricate 3D pie-shaped heterogeneous tissue constructs. The pie-shaped constructs were comprised of three distinct sections each with a particular cell type as shown in Fig. 5B1 . Similarly, 3D cuboidal homogenous tissue constructs of each cell type were also fabricated. Later, bioprinted constructs were cultured for one week and subcutaneously implanted into outbred athymic nude mice. Afterwards, the constructs were surgically retrieved either after four or eight weeks (see Fig. 5B2 ). Subsequent analysis showed that biological functions (i.e., viability, proliferation, phenotypic expression, and physiological properties) of the bioprinted cells of each type were not affected significantly both in vitro and in vivo. Another notable observation was the vascularization of implanted bEC constructs with substantial blood vessels compared to that of control groups.
On the other hand, achievements in regenerative medicine include tissue transplants [35, 92] and in-situ bioprinting [56] for improved wound healing. In a recent study [35] , Atala's group engineered hybrid cartilage tissue by employing micro-valve bioprinting and electrospinning. In that study, a bioink solution comprising chondrocytes, fibrinogen and collagen was bioprinted into previously electrospun layers of poly-ε-caprolactone (PCL) fibers as illustrated in Fig. 5C1e2 . In addition, thrombin was bioprinted on each bioprinted layer of the bioink solution to facilitate crosslinking. Afterwards, the constructs were cultured in vitro to evaluate cell proliferation and organization. Additionally, some constructs were cultured in vitro for two weeks and implanted subcutaneously in immunodeficient mice. Subsequently, the constructs were surgically retrieved after two, four, and eight weeks for characterization. The characterization study indicated that cartilage constructs maintained their biological functions both in vitro and in vivo. At the same time, the cartilage constructs possessed enhanced biological and mechanical characteristics than the cartilage constructs fabricated without incorporating the electrospun PCL fibers. Further, the constructs supported formation of a new cartilage-like tissue.
In-situ bioprinting is another achievement in regenerative medicine which is an alternative approach to two-step bioprinting (bioprinting followed by implantation), where cells and other biologics are directly bioprinted into lesion sites [56, 93] . In one study [56] , Lima's group engineered a cartilage tissue with comparable characteristics of the native cartilage. Using a TIJ bioprinter, human articular chondrocytes were bioprinted within photopolymerizable poly(ethylene) glycol dimethacrylate (PEGDMA) into circular defects in osteochondral explants. The explants were previously harvested from bovine femoral condyles using an 8-mm-diameter stainless steel punch. The defects in explants were repaired by bioprinting layers of chondrocytes and PEGDMA while crosslinking each bioprinted layer through photopolymerization. Afterwards, the repaired explants were cultured in vitro for two, four and six weeks post bioprinting. After four weeks, more chondrocytes with higher glycosaminoglycan (GAG) and collagen type II production were observed in tissue constructs bioprinted into the osteochondral explants than the constructs bioprinted in vitro (control group). Thus, in-situ bioprinting leveraged the presence of native cartilage tissue to accelerate chondrogenesis and extracellular matrix (ECM) production.
Similarly, Skardal and colleagues employed in-situ bioprinting to regenerate skin tissue with AFSCs and MSCs [93] . In order to compare their healing properties, the two cell types were separately bioprinted over surgical skin wounds (2.0 Â 2.0 cm) on the back (mid-dorsal region) of nude mice using a micro-valve bioprinter. Overall, three layers of thrombin solution and two layers of cell-laden collagen-fibrinogen solution were alternatively bioprinted over the wounds resulting in 5 Â 10 6 AFSCs or SMCs in each wound. Photographic images were taken immediately as well as seven and 14 days post-bioprinting to monitor wound healing. Furthermore, regenerated skin was harvested from animals at seven and 14 days for histological analysis. Results indicated that AFSCs were comparable to MSCs in skin regeneration and in-situ bioprinting of cells overall accelerated the wound healing process.
Application areas of droplet-based bioprinting
Droplet-based bioprinting has been utilized in various application areas including (i) tissue engineering and regenerative medicine, (ii) transplantation and clinics, (iii) drug testing and highthroughput screening, and (iv) cancer research [128] .
Tissue engineering and regenerative medicine
Engineering of tissues with comparable biological, anatomical, and physiological characteristics of their native counterparts is a great challenge [35] . Droplet-based bioprinting enables engineering tissues with native-like characteristics because of its ability to place various cell types accurately at a time [100] . It has been used to engineer tissues including bone [61, 88] , cardiac [57] , cartilage [33, 35, 59] , liver [9, 32] , lung [91] , neural tissue [34, 81] , skin [58, 92, 93] , vascular tissue [67, 94, 95] and ovarian tumor tissue [38] . Various tissue types fabricated using DBB and other bioprinting modalities are compared in Table 4 .
Bone tissue was engineered by Campbell's group in one study [101] by stimulating growth factor-dose-dependent differentiation of MDSCs towards osteogenic (bone) lineage employing BMP-2. Primary muscle-derived stem cells were cultured on BMP-2 patterns which were bioprinted on fibrin substrates using a PIJ bioprinter. The specificity of BMP-2 patterns essentially directed the dose-dependent differentiation of MDSCs. Similarly, Cui's group in another study [100] engineered bone-like tissue with increased compressive modulus using a TIJ bioprinter. Human mesenchymal stem cells, photopolymerizable PEGDMA, and HA nanoparticles were simultaneously bioprinted at predefined 3D locations. The nanoparticles closely mimicked the native tissue microenvironments and stimulated the differentiation of stems cells towards osteogenic lineage with improved mechanical characteristics.
Cardiac (heart) tissue with beating response was engineered in one study using feline cardiomyoctyes, HL1 cardiac muscle cells and alginate hydrogel precursor [57] . The tissue was fabricated by bioprinting consecutive layers of CaCl 2 on-demand at predefined locations using a TIJ bioprinter. After each layer was bioprinted, the substrate (mounted on a z-stage-stepper motor assembly) was submerged into a chamber filled with alginate hydrogel precursor solution (loaded with cells) to facilitate crosslinking. Subsequently, the substrate was brought up 100 mm below the initial position and the printing of CaCl 2 was resumed. As cardiac cells are anchorage dependent and their attachment is governed by mechanical characteristics of the matrix, the periodic beating response of the individual bioprinted cells as well as the 3D tissue constructs as a whole suggested that cardiac cells attached to the alginate as it effectively mimicked the native cardiac ECM.
Cartilage tissue was engineered in three recent studies [33, 35, 56] . Atala's group fabricated cartilage tissue by bioprinting chondrocytes, fibrinogen, and collagen at predefined locations over a previously electrospun layer of PCL fibers using a micro-valve bioprinter [35] . Subsequently, thrombin was bioprinted to facilitate gelation. Meanwhile, Demirci's group fabricated a fibrocartilage tissue model through the directed differentiation of the bioprinted hMSCs with BMP-2 and TGF-b1 [33] . Human MSCs were bioprinted using a micro-valve bioprinter together with photopolymerizable GelMA as well as the growth factors. The growth factors stimulated the differentiation of stem cells towards osteogenic and chondrogenic lineages, which was confirmed with quantitative reverse transcription polymerase chain reaction (RT-PCR) genomic expression analysis. Contrastingly, Lima's group fabricated cartilage tissue through in-situ bioprinting [56] as discussed in detail in Section 5.1.
Liver tissue was engineered in two individual studies conducted by Akashi et al. [9] and Shu et al. [32] . Akashi's group bioprinted liver tissue through layer-by-layer deposition of hepatocytes, endothelial cells, fibronectin, and gelatin using a PIJ bioprinter [9] . In that study, a single-layer to three-layer tissue models comprising of hepatocytes and liver endothelial cells (one layer of HepG2, two layers of HUVEC/HepG2, and three layers of HUVEC/HepG2/HUVEC) were fabricated. The tissue models were used for evaluating drug metabolism of anti-diabetic drug troglitazone. Similarly, Shu's group fabricated liver tissue with hepatocytes derived from hiPSCs and hESCs [32] as mentioned earlier in Section 5.1.
Lung tissue was engineered by Rothen-Rutishauser's group in a recent study [124] . The group fabricated an air-blood barrier model by bioprinting three distinct layers including alveolar epithelial type II (A549) cells, endothelial (EA.hy926) cells, and Matrigel™. A micro-valve bioprinter was employed for bioprinting the two cell types Neural tissue was engineered by Yoo's group in two studies using a micro-valve bioprinter. In the first study [87] , neural tissue was fabricated by bioprinting eight alternating layers of either collagen precursor and rat embryonic neurons or collagen precursor and astrocytes with rat embryonic neurons. Each bioprinted layer of cells was separated by two bioprinted layers of collagen precursor solution. In addition, each bioprinted layer of collagen precursor solution was crosslinked with sodium bicarbonate (NaHCO 3 ) mist (droplets of diameter < 2 mm) before bioprinting the subsequent layers. In the second study [34] , neural tissue was fabricated by stimulating the differentiation of neural stem cells (NSCs) using vascular endothelial growth factor (VEGF). The bioprinted tissue comprised of a single layer of NSCs and an adjacent circular layer of fibrin comprising VEGF which were sandwiched between two layers of collagen. In that study, stem cells neither proliferated nor migrated when the growth factors were absent.
Skin tissue was engineered recently in three studies [92, 93, 129] . Karande et al. in one study generated skin tissue in vitro with comparable biological and morphological characteristics of the native human skin [129] . The tissue was fabricated by bioprinting alternating layers of collagen, fibroblasts and keratinocytes using a micro-valve bioprinter. Initially, two layers of collagen precursor were bioprinted and each layer was crosslinked with NaHCO 3 vapor. Subsequently, a layer of fibroblasts was bioprinted. Bioprinting of two collagen precursor layers followed by bioprinting of a single layer of fibroblasts was continued until six layers of collagen and three intermediate layers of fibroblasts were bioprinted. Finally, two layers of collagen followed by two layers of keratinocytes were bioprinted to complete the tissue fabrication. The bioprinted tissue constructs were partially submerged in culture medium and were cultured for 4e8 days. That is, keratinocytes were cultured at the air-liquid interface to promote their differentiation into corneocytes as well as the formation of stratum corneum. Subsequent histological characterization of the mature tissue cultures revealed that fibroblast density in the dermis was relatively lower and the ordered stratification of keratinocytes was incomplete when compared to native human skin. In summary, biological and morphological characteristics of the bioprinted skin tissue were comparable to native human skin. Boland's group in another study [92] improved wound healing through bioprinted skin grafts. The skin grafts were fabricated by pipetting fibrinogen solution onto a layer of neonatal human dermal fibroblasts (NHDFs)-laden collagen. Subsequently, a layer of HMVECs-laden thrombin was bioprinted using a TIJ bioprinter onto fibrinogen. As a result, a fibrin-HMVEC layer was formed on the top of collagen-NHDF layer because of the interaction between fibrinogen and thrombin. Finally, neonatal human epidermal keratinocytes (NHEKs)-laden collagen was pipetted onto the fibrin-HMVEC layer. The grafts were incubated for 24 h and were transplanted onto the previously made surgical wounds (skin incisions of 2 mm deep and 1.7 Â 1.7 cm wide) of nude mice. The wounds with grafted skin were completely healed in 14e16 days where as the wounds without the grafts (control group) healed in 21 days. Furthermore, the grafts supported the formation of new skin with comparable morphological characteristics of native skin but lacked sebaceous glands (SG), hair follicles and hair bulbs. At the same time, wounds without grafts suffered extensive scarring. In an alternative approach, Soker's group employed in-situ bioprinting to regenerate skin tissue with AFS cells and MSCs [93] as discussed earlier in Section 7.1.
Vascular tissue was recently engineered by Dai's group [130, 131] . The group engineered capillaries through angiogenic sprouting of endothelial cells between two parallel vascular fluidic channels within a collagen construct [130] . Angiogenic sprouting of vascular networks is absolutely vital for tissue constructs at the clinically-relevant dimensions as vascularization of engineered tissue constructs has been elusive and remained obstacle on fabricating functional replacement human organs [4] . Angiogenic sprouting is a step towards addressing that challenge [114] . Fig. 5D shows sprouted micro-capillaries out of bioprinted human umbilical vein endothelial cells (HUVECs) transfected with green fluorescent protein (GFP) and between the vascular channels seeded with HUVECs transfected with red fluorescent protein (RFP), 14 days post-bioprinting. Normal human lung fibroblasts (NHLFs) and GFP-transfected HUVECs were bioprinted in fibrinogen between the channels. Each bioprinted layer of fibrinogen was subsequently crosslinked with thrombin to facilitate fibrin formation. Capillaries between the two vascular channels began to sprout as early as day three.
Transplantation and clinics
Although a wide array of tissue types, such as skin [92] , composite tissue [17] , cartilage [35] , bone [132] and vascular tissue [133] , have been bioprinted using DBB technology and transplanted into animal models, translation of droplet-based bioprinted tissues into clinics for human use still remains elusive. Currently, a single exemplary case [134] demonstrated the transplantation of a 3D printed biodegradable airway splint, made of PCL, into an infant after the approval of Food and Drug Administration (FDA) under the emergency-use exemption along with a written consent of the patient's parents. Although that study did not involve any cell or tissue printing attempt, translation of 3D printed scaffolds into clinics will be inspirational for bioprinting research and the case sets a precedent for translating bioprinting technologies from bench to bedside. In this regard, in-situ bioprinting technology is highly promising as cells and biologics can be bioprinted directly into the defect or wounded site on human body to repair body parts in operating settings. This technology, has been attempted using DBB technologies such as bioprinting of growth factors in cranium defects on rodent models [132] or bioprinting of skin cells on large deep wounds on rodent models [93] . Droplet-based bioprinting is the most convenient modality of bioprinting to deposit biologics into defects in surgery settings as it is a non-contact-based modality and does not entail any toxic and unsafe interventions during the surgery. Although the technology has been tested for animal models only, clinical translation will necessitate further advancements, testing and approval through regulatory pathway with the FDA. Bioprinting with growth factors and other biologics without using cells can transition earlier and further modifications can be pursued along the way with incorporating patient-specific cells into in-situ bioprinting technology. Food and Drug Administration has not imposed and laid down any regulations for the bioprinting technology and its components including bioink, bioprinters and bioprinted tissues and organs, and it is not clear how this technology will be categorized. Nonetheless, in-situ bioprinting is highly convenient for organs that are outside the body and accessible, and can be used for skin regeneration, maxillo-and cranio-facial reconstruction, plastic surgeries, tissue flaps or composite tissues repair for limb reconstruction.
Drug testing and high-throughput screening
Although micro-engineering techniques, such as surface patterning, soft-lithography and micro-fluidic-based manipulation [135] have been utilized in drug testing and high-throughput screening, DBB provides greater advantages such as highprecision control, repeatability and uniformity for fabrication of 3D micro-arrays. In this regard, Demirci and his coworkers demonstrated an acoustic-based bioprinting platform to bioprint a micro-array of SMCs on a collagen substrate [136] . The generated micro-array was then stimulated with different environmental conditions, such as temperature, in order to investigate the effect of the applied stimuli on cell fate. In a more recent study, Xu et al. presented an inkjet-based bioprinting approach to assemble a high-throughput miniature drug-screening platform [38] . A modified HP model 5360 compact disc printer was used to bioprint E. coli-laden alginate to generate a micro-array on a coverslip, followed by bioprinting of three different antibiotics (including penicillin/streptomycin, antimycotic, and kanamycin sulfate) on top of the bioprinted bacteria-laden hydrogel as shown in Fig. 5E1e2 . The results revealed that the TIJ-bioprinted samples demonstrated similar cell viability and functionality, and antibacterial effects of antibiotics compare to micro-pipetted samples, confirming that TIJ bioprinting is as a powerful method to generate high-throughput arrays of samples for drug screening applications. In another work, Matsusaki et al. presented PIJ bioprinting of multi-layer liver tissue models on a 440 micro-well plate for drug screening and high-throughput applications [9] . In that work, a single-layer to three-layer tissue models comprising of hepatocytes and liver endothelial cells (one layer of HepG2, two layers of HUVEC/HepG2, and three layers of HUVEC/HepG2/ HUVEC) were fabricated. Subsequently, the anti-diabetic drug troglitazone was used to evaluate the drug metabolism activity of tissue models by culturing them for a week. Albumin and CYP3A4 production in the cultured tissue models increased significantly with an increase in number of constituent cell layers. Thus, the presented work clearly demonstrated the potential of inkjet bioprinting for fabrication of a high-throughput liver tissue model for drug screening. Integration of DBB with microfluidics and microwell technology is new and our recent opinion article discusses how DBB can be used to bioprint multiple cell types into microwells for fabrication of heterocellular tissue models with controlled cell ratio and tissue size [137] .
Cancer research
Mimicking a 3D cancer microenvironment is highly vital in order to understand cancer pathogenesis and metastasis [40] . Therefore, DBB has the great advantage in fabrication of highresolution tissue models with great repeatability. In the literature, only a few works have demonstrated DBB for cancer research as bioprinting has been recently adapted into this application area. In this regard, Demirci's group demonstrated bioprinting of tumor tissue models for in-vitro assays [40] , where OVCAR-5 cells and MRC-5 fibroblasts were jetted using a dual-ejector system focusing on the same point. These two cell types were spontaneously bioprinted on Matrigel™ to generate multicellular acini in a highthroughput and reproducible manner with a spatially-mediated microenvironment with controlled cell density and cell-cell distance as illustrated in Fig. 5F . The resultant high post-bioprinting viability of the cells demonstrated the capability of DBB for invitro disease modeling and investigation of complex cell-to-cell communications including unknown regulatory mechanisms among various cell types.
Future prospects
Different bioprinting modalities, including DBB, are envisioned to fabricate functional replacement human organs in the future [10, 138] ; however, several challenges have yet to be overcome to make it a reality. The first challenge is the printhead design for DBB. The physical characteristics of currently available printheads limit the control over several parameters including droplet volume, the number of cells to be encapsulated in each droplet, the precise placement of droplets, cell concentration, bioink material properties (viscosity) and the long-term reliability of the entire system. Printhead design constraints arise because of the current microfabrication processes, which impose several restrictions including the nozzle geometry. Hence, new nano-or micro-fabrication techniques are required to overcome the physical limitations with novel nozzle and printhead designs.
The second challenge is associated with materials that constitute the bioink. Each human organ is comprised of several billions of cells of various types [139] . Hence, acquiring cells such as stem cells in such quantities for autologous transplantation applications is constrained by cell cycle times, which may take several weeks to months [140, 141] . Hence, new strategies for accelerating the cell cycle time are required. Another bioink-related challenge is the availability of biomimetic materials with controlled degradability and signaling cues to stimulate the proliferation and differentiation of cells [3] . For example, matrix material properties, such as elasticity, impacts the differentiation of bioprinted cells into specific phenotypes [142] . Thus, development of new materials or mechanisms that instill the bioink material with specific biomimetic characteristics, particularly after bioprinting, is desired as the nozzle geometry imposes material constraints. Growth factors and other signaling molecules could partially reduce the necessity of biomimetic materials; however, transporting them to specific bioprinted cells in a sustained manner over time imposes its own set of challenges. Perhaps, the transport of targeted growth factors and signaling molecules is possible by controlling the micro-pore geometry of bioprinted hydrogels such that of molecules of particular conformation (shape) are selectively transported.
The third challenge is the fabrication of 3D tissue constructs of complex conformations at sub-micrometer to micrometer resolution. For example, fabrication of complete vascular network at the single-cell level is challenging because DBB at high resolution is limited by the nozzle geometry, which constraints the droplet volume (size) and the bioink viscosity. Moreover, available bioprintable materials or hydrogels are characterized by weak mechanical strength and hence simultaneous co-deposition of degradable and biocompatible support materials is essential for counteracting gravity. Although, strategies such as support by means of liquid buoyancy have been proposed [60] , leveraging natural mechanisms of cells is potentially most effective of all as it addresses several challenges at once. For instance, angiogenesis of micro-capillaries [130] obviates the co-deposition of support materials and the development of novel printheads with extremely small orifice diameter.
Currently, DBB is not capable of fabricating functional replacement human organs at clinically-relevant dimensions; however, it can improve drug discovery and disease modeling as it enables fabrication of spatially-patterned-multicellular microenvironments in a high-throughput and reproducible manner. Further, only a tiny tissue model can be sufficient for drug screening. At present, many drugs are not effective. For example, 97% of the patients see no benefits from anti-hypertensives [143] given for high blood pressure whereas 98% of the patients see no benefits from statins given for high cholesterol [144] . The low efficacy of prescription drugs can be attributed to the low numbers of human test subjects [145] , which may not account for the genetic diversity among millions of patients. Bioprinted organ-on-a-chip models based on hiPSCs derived from diverse groups can account for the genetic variations and improve the drug discovery. Further, genomic analysis tools and individual genetic tests are becoming inexpensive and they can be used to personalize treatment plans or drug doses. Moreover, 3D tissue models are better at mimicking human physiology and pathology than currently used 2D cell culture models [10, 12, 14] as well as the animal models [13] . Hence, DBB in combination with targeted genome editing tools such as CRISPR (clustered regularly interspaced short palindromic repeats)/CAS9 [146, 147] can improve disease modeling [148, 149] .
Conclusions
Droplet-based bioprinting offers great advantages due to its simplicity, agility and versatility with great control on the deposition pattern. Although the technology currently enables fabrication of heterocellular tissue constructs in a high-throughput and reproducible manner, and has been widely used in several application areas such as tissue engineering and regenerative medicine, transplantation, drug testing and high-throughput screening, and cancer research, the technology currently faces several limitations such as weak structural and mechanical properties of bioprinted tissue and organ constructs as well as their lack of vascularization and perfusability, and the limited translation of the technology into clinics. Despite these limitations, novel breakthroughs such as angiogenesis and in-situ bioprinting, which leverage nature-driven mechanisms, make the eventual clinical translation of DBB technology inevitable.
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